Ceftaroline fosamil

Structural formula
General
Non-proprietary name	Ceftaroline fosamil
other names	(6 R , 7 R ) -7 - {[(2 Z ) - (ethoxyimino) [5- (phosphonoamino) -1,2,4-thiadiazol-3-yl] acetyl] amino} -3- [4- ( 1-methylpyridinium-4-yl) thiazol-2-yl] sulfanyl-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-en-2-carboxylate; TAK-599;
Molecular formula	C 22 H 21 N 8 O 8 PS 4
External identifiers / databases
PubChem	9852981
ChemSpider	8028692
DrugBank	DB06590
Wikidata	Q409712
Drug information
ATC code	J01 DI02
Drug class	antibiotic
properties
Molar mass	684.7 g · mol -1
safety instructions
	Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed
GHS hazard labeling ; no classification available
	As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Ceftaroline Fosamil is a medicinal substance with an antibiotic effect .

It is the N- phosphono - prodrug of Ceftarolin, a cephalosporin antibiotic 5th generation with high efficacy against methicillin-resistant staphylococci (MRSA) and other multi-resistant problem bacteria ( VISA , VRSA , PRSP ), and against gram-negative bacteria , but not against ESBL -generating Enterobacteriaceae and non-fermenters.

It was developed by the Japanese pharmaceutical company Takeda and approved by the FDA as Teflaro in October 2010 for the parenteral treatment of adults with community-acquired pneumonia and acute skin and soft tissue infections. In August 2012 the approval for the EU countries followed under the name Zinforo . The active ingredient is used pharmaceutically as the salt of acetic acid , ceftaroline fosamil acetate monohydrate .

literature

P. Jungmayr: New weapon against problem germs , Deutsche Apothekerzeitung, January 24, 2013.
Andes, D .; Craig, WA; Antimicrobial Agents and Chemotherapy , 50 (4), 1376-1383, 2006.
Jaqueline, C .; Caillon, J .; Le Mabecque, V .; Miegeville, A .; Hamel, A .; Bugnon, D .; Yiong Ge, J .; Potel, G .; Antimicrobial Agents and Chemotherapy , 51 (9), 3397-3400, 2007.
Talbot, GH; Thye, D .; The A.; Ge, Y .; Antimicrobial Agents and Chemotherapy , 51 (10), 3612-3616, 2007.
Parish, D .; Scheinefeld, N .; Current Opinion in Investigational Drugs , 9 (2), 201-209, 2008.

Individual evidence

↑ This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.
↑ FDA Approves Teflaro for Bacterial Infections , FDA News Release, October 29, 2010.
↑ Zinforo on the website of the European Medicines Agency.
↑ External identifiers or database links for ceftaroline fosamilacetate (1: 1) 1 H ₂ O : CAS number: 400827-55-6, EC number: 807-903-6, ECHA InfoCard: 100.235.826 , PubChem : 56841981 , Wikidata : Q72515487 . Molar mass: 762.75 g mol ⁻¹ .

[NV-1] This substance has either not yet been classified with regard to its hazardousness or a reliable and citable source has not yet been found.

[2] FDA Approves Teflaro for Bacterial Infections , FDA News Release, October 29, 2010.

[3] Zinforo on the website of the European Medicines Agency.

[4] External identifiers or database links for ceftaroline fosamilacetate (1: 1) 1 H ₂ O : CAS number: 400827-55-6, EC number: 807-903-6, ECHA InfoCard: 100.235.826 , PubChem : 56841981 , Wikidata : Q72515487 . Molar mass: 762.75 g mol ⁻¹ .